Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
NCT ID: NCT02807285
Last Updated: 2017-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
NCT02688985
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02861014
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
NCT04377555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ocrelizumab
Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of PPMS in accordance with the revised 2010 McDonald criteria and the presence or documented history of cerebrospinal fluid oligoclonal bands by isoelectric focusing or elevated immunoglobulin G (IgG) index
* Expanded Disability Status Score (EDSS) of 2.0 to 6.5 points at screening
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<)1 percent (%) per year during the treatment period and for at least 24 weeks after the last dose of study treatment or until their B-cells have repleted, whichever is longer
Exclusion Criteria
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
* History or known presence of recurrent or chronic infection
* History of recurrent aspiration pneumonia requiring antibiotic therapy
* History of cancer, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)
* History of or currently active primary or secondary immunodeficiency
* History of coagulation disorders because ocrelizumab is administered via infusion
* Known presence or history of other neurologic disorders
* Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including chronic obstructive pulmonary disease), renal, hepatic, endocrine, gastrointestinal, or any other significant disease
* Congestive heart failure
* Known active bacterial, viral, fungal, mycobacterial infection, or other infection
* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the expanded access program (EAP)
* Contraindications for or intolerance to oral or IV corticosteroids, including IV methylprednisolone
* Treatment with therapies approved for relapsing forms of Multiple Sclerosis (MS), including: Beta interferons, glatiramer acetate, fingolimod (Gilenya®), teriflunomide (Aubagio®), dimethyl fumarate (Tecfidera®), IV immunoglobulin, plasmapheresis, or other immunomodulatory therapies within 12 weeks prior to enrollment (Participants should not be excluded from the EAP due to previous treatment with rituximab)
* Participants who have received fingolimod (Gilenya®) or dimethyl fumarate (Tecfidera®) if their lymphocyte count is not within normal values
* Previous treatment with natalizumab (Tysabri®) within 6 months of screening (Participants are not eligible for the EAP if they have been treated with natalizumab (Tysabri) for more than 1 year)
* Any previous treatment with alemtuzumab (Lemtrada®)
* Any previous or current treatment with any experimental procedure for MS
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Neurological Associates Ltd
Phoenix, Arizona, United States
Territory Neurology and Research Institute
Tucson, Arizona, United States
Mercy Medical Group; MS Centre Nurse
Carmichael, California, United States
Scripps Clinic
La Jolla, California, United States
MS Center of Southern California
Newport Beach, California, United States
Stanford University
Palo Alto, California, United States
Neuro-Therapeutics Inc.
Pasadena, California, United States
UCSF- Multiple Sclerosis Centre; Department of Neurology
San Francisco, California, United States
University Of Colorado
Aurora, Colorado, United States
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado, United States
Associated Neurologists of Southern CT PC
Fairfield, Connecticut, United States
Neurology Associates
Norwich, Connecticut, United States
University of Miami Miller School of Medicine; Clinical Reseach Building
Miami, Florida, United States
Neurological Services of Orlando
Orlando, Florida, United States
Infinity Clinical Research, LLC
Sunrise, Florida, United States
University of South Florida
Tampa, Florida, United States
MS Center of Vero Beach
Vero Beach, Florida, United States
Consultants in Neurology Ltd
Northbrook, Illinois, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Indiana University
Indianapolis, Indiana, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Norton Neurology Services
Louisville, Kentucky, United States
Steward St. Elizabeth's Medical Center
Boston, Massachusetts, United States
Wayne State Uni /Detroit Medical Center
Detroit, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan, United States
The Minneapolis Clinic of Neurology
Golden Valley, Minnesota, United States
Washington University
St Louis, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Rutgers New Jersey Medical School
Newark, New Jersey, United States
Holy Name Hospital
Teaneck, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
South Shore Neurologic Associates P.C.
Patchogue, New York, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
Carolinas Healthcare System
Charlotte, North Carolina, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center; Department of Neurology
Columbus, Ohio, United States
Neurology and Neuroscience Assoc., Inc.
Westerville, Ohio, United States
Oklahoma Medical Research Foundation; MS Center of Excellence
Oklahoma City, Oklahoma, United States
Providence Multiple Sclerosis Center
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Abington Neurological Associates
Willow Grove, Pennsylvania, United States
The Neurology Foundation, Inc.
Providence, Rhode Island, United States
Sibyl Wray MD Neurology PC
Knoxville, Tennessee, United States
Advanced Neurosciences Institute
Nashville, Tennessee, United States
University Of Texas Health Science Center Houston
Houston, Texas, United States
Central Texas Neurology Consultants
Round Rock, Texas, United States
Neurology Center of San Antonio
San Antonio, Texas, United States
University of Vermont
Burlington, Vermont, United States
Neurological Associates Inc; Clinical Research
Richmond, Virginia, United States
Swedish Neuroscience Institute; Multiple Sclerosis Center
Seattle, Washington, United States
Multicare Neuroscience Center of Washington
Tacoma, Washington, United States
Columbia St. Mary's Hospital System
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29972
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.